Fluticasone Furoate Ellipta Powder
NDC Package 66993-166-97
Package Information
Fluticasone Furoate Ellipta (fluticasone furoate) powders is fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. This formulation utilizes a powder delivery system. Marketed by Prasco Laboratories, this product is identified by NDC 66993-166 and is authorized under FDA application NDA205625.
Identification & Billing
- RxCUI: 1547658 - fluticasone furoate 100 MCG/INHAL Dry Powder Inhaler, 30 Blisters
- RxCUI: 1547658 - 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT Dry Powder Inhaler
- RxCUI: 1547658 - fluticasone furoate 100 MCG/ACTUAT Dry Powder Inhaler, 30 ACTUAT
- RxCUI: 1547671 - fluticasone furoate 200 MCG/INHAL Dry Powder Inhaler, 30 Blisters
- RxCUI: 1547671 - 30 ACTUAT fluticasone furoate 0.2 MG/ACTUAT Dry Powder Inhaler
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 66993 - Prasco Laboratories
- 66993-166 - Fluticasone Furoate Ellipta
- 66993-166-97 - 1 INHALER in 1 CARTON / 30 POWDER in 1 INHALER
- 66993-166 - Fluticasone Furoate Ellipta
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 66993-166-97 identifies a specific commercial package of 1 inhaler in 1 carton / 30 powder in 1 inhaler of Fluticasone Furoate Ellipta, a human prescription drug labeled by Prasco Laboratories. This powder is formulated for respiratory (inhalation) use and contains fluticasone furoate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prasco Laboratories on July 21, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.
How is this Prasco Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 66993016697. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.